• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Hoffman John Francis

    5/23/25 4:15:32 PM ET
    $ATAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATAI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hoffman John Francis

    (Last) (First) (Middle)
    WALLSTRASSE 16

    (Street)
    BERLIN 2M 10179

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/15/2025
    3. Issuer Name and Ticker or Trading Symbol
    ATAI Life Sciences N.V. [ ATAI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney.
    No securities are beneficially owned.
    /s/ Ryan Barrett, Attorney-in-fact 05/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ATAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATAI

    DatePrice TargetRatingAnalyst
    4/4/2025Buy
    Berenberg
    11/18/2024$15.00 → $10.00Buy
    H.C. Wainwright
    4/3/2024$6.00Hold → Buy
    Maxim Group
    11/1/2022$18.00Buy
    Loop Capital
    11/30/2021$25.00Buy
    Maxim Group
    11/22/2021$40.00 → $50.00Buy
    HC Wainwright & Co.
    11/16/2021$25.00 → $24.00Outperform
    Credit Suisse
    11/16/2021$19.00 → $17.00Sector Perform
    RBC Capital
    More analyst ratings

    $ATAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Angermayer Christian

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      6/4/25 4:38:51 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hoffman John Francis

      3 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      5/23/25 4:15:32 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Short Glenn Frank sold $17,767 worth of shares (13,161 units at $1.35), decreasing direct ownership by 24% to 42,333 units (SEC Form 4)

      4 - ATAI Life Sciences N.V. (0001840904) (Issuer)

      3/24/25 9:00:05 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

      Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinicCombined company will operate under the name atai Beckley with a joint leadership team and Board that leverage the deep psychedelic, drug development and CNS expertise within both organizationsTopline data from the Phase 2b study of BPL-003 in patients with treatment-resistant depression (TRD) is expected in mid-2025 - the largest controlled trial of mebufotenin (5-MeO-DMT) and the first and only controlled trial to investigate mebufotenin in the U.S

      6/2/25 6:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences to Participate in Upcoming Investor Conferences

      NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences  (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company's management team is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference Format: Fireside ChatDate and Time: Thursday, June 5 at 9:55 A.M. EDTLocation: New YorkWebcast link: here H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Format: Pre-recorded Fireside ChatDate and Time: Tuesday, June 17 at 7:00 A.M. EDTLocation: VirtualWebcast l

      5/29/25 8:30:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

      - Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing - Data from the eight-week core, randomized stage of Beckley Psytech's Phase 2b study of BPL-003 for treatment-resistant depression is expected in mid-2025 NEW YORK and BERLIN, May 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform p

      5/20/25 7:00:00 AM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATAI
    SEC Filings

    See more
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      6/17/25 9:50:49 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      6/2/25 9:15:50 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by ATAI Life Sciences N.V.

      DEFA14A - ATAI Life Sciences N.V. (0001840904) (Filer)

      6/2/25 5:17:11 PM ET
      $ATAI
      Biotechnology: Pharmaceutical Preparations
      Health Care